Author/Authors :
Meghrajani, Vineet Department of Internal Medicine - Maimonides Medical Center, Brooklyn, NY, USA , Hashmi, Arsalan Department of Internal Medicine - Maimonides Medical Center, Brooklyn, NY, USA , Cheng Lin, Shuo Department of Internal Medicine - Maimonides Medical Center, Brooklyn, NY, USA , Plawes, Zvi Department of Cardiology - Maimonides Medical Center, Brooklyn, NY, USA , Brejt, Shelly Department of Cardiology - Maimonides Medical Center, Brooklyn, NY, USA
Abstract :
We present a 64-year-old woman who developed symptoms of acute pericarditis three days after undergoing intravesical instillation of mitomycin C following transurethral bladder tumor resection. Mitomycin C is a chemotherapeutic agent which acts
by alkylation of DNA and is known to be cardiotoxic when systemically administered. Despite classic pericarditis symptoms, the
patient underwent an urgent coronary angiogram due to elevated cardiac troponin I level, EKG changes, and wall motion
abnormalities on her echocardiogram. During her angiogram, it was found that she had multiple stenotic coronary artery lesions,
with no acute total coronary occlusions, and percutaneous coronary intervention (PCI) was done with placement of a single drugeluting stent for a 95% stenotic lesion in the left anterior descending artery. ,e patient was discharged after an uneventful
hospitalization on dual antiplatelet therapy with aspirin and prasugrel, and colchicine for pericarditis. It is likely that the patient’s
presentation was the result of a perimyocardial inflammatory process secondary to intravesically administered mitomycin C,
rather than an acute coronary syndrome. While the pathophysiological basis of cardiotoxicity of systemically administered
mitomycin C is well documented, more studies are needed to determine whether intravesical MMC may cause cardiotoxicity.